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Abstract. Maslinic acid is a pentacyclic triterpene found in plants 
used in traditional medicine with antidiabetic, antitumor, antioxidant 
and parasitostatic activities. A diet rich in foods of plant origin could 
provide a regular supply of this bioactive compound since it has 
been detected in olives, spinaches, eggplants, chickpeas and 
pomegranates. The multiple biological effects elicited by maslinic 
acid suggest its putative use as nutraceutical. This review 
summarizes our study on the safety, pharmacokinetics, and 
metabolism after the oral administration of maslinic acid, conducted 
with the aim of increasing the knowledge about the bioavailability 
of this bioactive food component. 
 
Introduction 
 
      The association between nutrition and human health is not a novel 
concept, since Ayurveda and Chinese medicine had already endorsed food as 
medicine, either as prevention for the development of certain ailments or as     
a treatment. This association was promoted by Hippocrates (460–377 BC) in 
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his principle “Let food be thy medicine, and medicine be thy food”. The 
relationship between nutrition and health has encouraged research on 
bioactive food components that could improve the physical and mental well-
being and reduce the risk of disease. Among the different food from the diet, 
those from vegetable origin have been strongly associated with a reduced 
risk of developing chronic diseases, due to the presence of phytochemicals 
that are non-nutritive secondary metabolites. These bioactive compounds 
may have a lower potency if they are compared to drugs. However, 
phytochemicals could impact on health given that they are ingested regularly 
as part of the diet [1]. Different dietary molecules have been associated with 
physiological effects, such as glucosinolates, carotenoids, polyphenols and 
triterpenoids. Among the latter, stands out maslinic acid, which is currently 
in the early stages of the pre-clinical phase of research, as evidenced by the 
fact that the vast majority of published references mainly consisted of                
in vitro studies, with only a few studies conducted in vivo. Maslinic acid has 
been described to exert several biological activities, such as antidiabetic, 
antitumor, antioxidant and parasitostatic, among others [2]. Therefore, the 
present chapter focuses on the recent research in our group that has been 
aimed at assessing the safety of maslinic acid and at evaluating its 
bioavailability after oral administration.   
 
1. Chemistry of maslinic acid 
 
 Maslinic acid or (2α,3β)-2,3-dihydroxyolean-12-en-28-oic acid (Fig. 1) 
was first isolated in 1927 from the leaves of Crataegus oxyacantha L. and 
was named “crategolic acid” [3].    
 The identification of this compound in Olea europaea L. came in 1961 
when Caglioti et al. [4] found in olive husk a triterpenic compound with 
the same molecular formula and chemical structure as crategolic acid and 
termed it maslinic acid. The same year, Vioque and Morris [5] detected 
this pentacyclic triterpene in olive pomace. However, it was not until 1994 
that Bianchi and coworkers [6] established that maslinic acid was the main 
pentacyclic triterpene in olives. 
 The biosynthetic pathway has been recently postulated in Olea 
europaea L. [7], where it has been suggested that sterols (primary 
metabolites) and non-steroidal triterpenoids (secondary metabolites) share 
2,3-oxidosqualene as a common precursor. The cyclization of 2,3-oxidosqualene 
leads to the oleanyl cation as a precursor of erythrodiol, which is the first 
derivative of ß-amyrin. Further oxidation steps yield to the formation of  
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Figure 1. Chemical structure of maslinic acid. 
 
oleanolic acid and its isomer maslinic acid. In the plant, maslinic acid acts 
as a phytoalexin that is a secondary metabolite involved in the protection 
against pathogens [8].  
 
2. Sources of maslinic acid 
 
 Maslinic acid is broadly distributed in the plant kingdom, being detected 
in more than 30 species worldwide. This pentacyclic triterpene has been 
found in plants used in traditional medicine for the treatment of diverse 
affections. The leaves of banaba or Lagerstroemia speciose L. are especially 
rich in maslinic acid (4.96 ± 0.13 mg/g) [9]. The extracts of the banaba have 
been used for many years in folk medicine for the treatment of diabetes. 
Crataegus monogyna L., commonly known as hawthorn, contain 0.93 ± 0.07 
mg/g of maslinic acid [9] and has been used as a remedy for the 
cardiovascular system given its hypotensive, antioxidant, anti-inflammatory, 
and vasodilating effects, among others. Ortosiphon stamineus L. possesses 
several pharmacological activities such as diuretic, hepatoprotective, 
antidiabetic, antihyperlipidemic, and has been described to have 0.84 ± 0.06 
mg/g of maslinic acid [9]. Moreover, this pentacyclic triterpene has been 
described in Eriobotrya japonica, employed as antitussive and anti-
inflammatory for chronic bronquitis as well as diuretic [10], Geum 
japonicum employed as diuretic [11], and Agastache rugose used in the 
treatment of intestinal disorders [12].  
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  Maslinic acid has also been described in several edible plants that 
could provide a constant supply of this compound, especially in the 
countries bordering the Mediterranean Sea where the diet is rich in fruits 
and vegetables, olive oil is used for cooking as well as salad dressing and 
table olives are consumed as appetizer. The latter are a food with a 
particularly high content in maslinic acid although the concentration 
depend on the fruit variety and the method of elaboration. In fruits 
processed with natural fermentation, the concentrations of maslinic acid 
ranged from 1.32 ± 0.4 g/g fresh olive pulp in Kalamata to 0.28 ± 0.07 g/g 
fresh olive pulp in Manzanilla variety [13]. Virgin olive oil is obtained in a 
process involving pressing, which may disrupt the surface waxes on the 
fruit. Therefore, part of maslinic acid contained in the olive may be 
transferred to the oil. However, the amount of this pentacyclic triterpene in 
the oil is much lower than in the fruit, and depends on the oil quality. Extra 
virgin olive oil, with an acidity under 1% contains 64.2 ± 8.1 mg/kg of 
maslinic acid, an amount that increases to 193.9 ± 14.0 mg/kg in virgin 
olive oil, since the hydrolytic process that takes place during the extraction 
enables the release of this compound from the cuticular layer [14]. The 
presence of this compound has been reported in spinach (1260 mg/kg dry 
weight), eggplants (840 mg/kg dry weight), chickpeas (62 mg/kg dry 
weight), large lentils (40 mg/kg dry weight), and aromatic herbs such as 
basil (350 mg/kg dry weight) [15,16]. Maslinic acid has also been found in 
fruits, like kiwi (17.3 mg/kg), pomegranate (10.8 mg/kg), or mandarin 
(10.8 mg/kg) [17]. 
 
3. Toxicology 
 
 The beneficial effects on health described for maslinic acid granted the 
use of this compound as a possible nutraceutical. However, the safety of this 
bioactive compound needed to be assessed. Accordingly, the effect of high 
doses of maslinic acid on Swiss CD-1 mice were evaluated following the 
indications given by the Organization for Economic Cooperation and 
Development (OECD) guidelines [18] for the evaluation of preclinical acute 
and subacute toxicities. In first place, the effect of the single oral 
administration of maslinic acid was assessed by administering 1000 mg/kg 
to two adult Swiss CD-1 mice. The acute toxicity study was conducted in 
order to evaluate if the administration of a single high dose of this 
pentacyclic triterpene exerted any adverse effect on the animals over the 
immediately consecutive days. This evaluation of the acute toxicity showed 
that this pentacyclic triterpene did not have any negative effect on the 
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animals after the 15-day observation period in which body weight, food 
consumption as well as the general state of the animals was controlled, 
indicating that maslinic acid is practically nontoxic under these conditions 
[19].  
 In second place, the subacute toxicological evaluation was performed 
and consisted of the repeated oral administration for 28 days of maslinic acid 
at 50 mg/kg [19]. The dose selected corresponded to approximately 125 
times the amount that may be consumed by a person eating 40 g or 10-
medium sized olives and 33 g of olive oil a day. The results showed that no 
death or hazardous signs of toxicity were recorded during the experimental 
period. A decrease of a 13% was observed in the food intake of the treated 
mice compared to the controls, without affecting the body growth, which 
was equal in both groups [19]. A similar effect was indicated for the gilthead 
sea bream (Sparus aurata) that were fed with 100 mg/kg of maslinic acid for 
210, reporting a decrease in the relative intake of diet 18% lower in the fish 
fed with the triterpene with respect to the control group and an increase of 
body weight in the treated group of only a 5% [20]. No effect on body 
weight was observed after the administration of 20, 40, and 80 mg/kg to 
juvenile dentex (Dentex dentex) during 49 days [21]. By contrast, maslinic 
acid has been described to stimulate body growth in healthy fish thus being 
proposed as a feed additive in aquiculture [22]. Rainbow trout 
(Oncorhynchus mykiss) fed with 25 and 250 mg/kg of maslinic acid in the 
diet during 225 days increased body weight, compared to the control group, 
in 19.3% and 29.2%, respectively. This effect was attributed to a higher 
growth rate of white muscle, which was correlated with hyperplasia and 
hypertrophy in the tissue [22]. 
 The safety of maslinic acid was further evaluated by the assessment of 
hematology and clinical chemistry, which showed no differences between 
the control and the treated groups [19]. The absence of negative results 
obtained after the clinical chemistry evaluation corroborated that the 
treatment of mice with 50 mg/kg of maslinic acid did not compromise the 
overall health status of the animals since no alterations in metabolic 
processes in target organs were observed [19]. Worth mentioning is the 
point that maslinic acid did not have any significant effect on blood 
glucose in physiological conditions, despite being considered an anti-
diabetic agent in different models of hyperglycemia [23,24]. It could be 
considered a positive outcome, since it would imply that maslinic acid 
could avoid the side effects caused by hypoglycemic treatments. No effects 
were observed on the lipid profile [19].  
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 The lack of harmful effects exerted by the oral administration of                      
50 mg/kg of maslinic acid for 28 days was verified with a gross necropsy 
with the measurement of the organ weights and the histopathologic 
evaluation of the tissues [19]. The relative weight of liver, kidney, hear t, 
lungs, and spleen were not different from controls. Remarkable the fact 
that no liver hyperplasia was observed in our study, although it was 
reported that rainbow trout that ingested maslinic acid at the dose of 25 
and 250 mg/kg for 225 days displayed an increase of the liver size of 52% 
and 40% with respect to the controls [22]. The treatment of mice with 50 
mg/kg of maslinic acid, induced an increase on the relative weight of the 
brain of 11% (P < 0.05) higher than the control group, but changes in 
relative brain weight are rarely associated with neurotoxicity [25]. 
 Overall, the results obtained in the toxicological study that showed an 
absence of harmful effects found in the hematology, clinical biochemistry, 
and histopathology evaluation suggest a large safety margin for this 
pentacyclic triterpene after oral administration. 
 
4. Oral bioavailability of maslinic acid 
 
 The absence of adverse effects demonstrated for maslinic acid 
constituted a promising starting point for its future use as a nutraceutical 
due to the biological activities described for this pentacyclic triterpene.  
However, this information needed to be completed with a detailed study 
about its absorption, distribution, and metabolism either in humans or in 
animals after the consumption of this molecule. Bioactive compounds from 
food must be bioavailable in order to perform their beneficial effects on 
health. Therefore, bioavailability and metabolism of maslinic acid had to 
be explored in vivo in order to elucidate its mode of action and clarify the 
extent of its absorption and metabolism.  
 
4.1. Plasmatic concentrations of maslinic acid 
 
 The bioavailability of maslinic acid was assessed after the p.o. 
administration of 50 mg/kg and the i.v. administration of 1 mg/kg to 
overnight fasted male Sprague-Dawley rats. Blood was taken from the 
lateral saphenous vein at different time points from 1 min to 24 h in order 
to cover the whole plasma concentration versus time curve [26]. Sampling 
was performed following a sparse design with three to six replicates for 
each time point. Blood was centrifuged and plasma was separated from 
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cells, and frozen at -20 ºC until analysis. The method to determine maslinic 
acid from plasma consisted of two extractions with ethyl acetate, prior to 
evaporation to dryness and reconstitution with methanol 80%. This 
pentacyclic triterpene was detected by liquid chromatography-atmospheric 
pressure chemical ionization-mass spectrometry (LC-APCI-MS) [26].  
 The method to determine maslinic acid from plasma was validated 
according to the EMA Guidelines on Bioanalytical Method Validation 
[27]. The validation was performed with blank plasma samples spiked with 
maslinic acid at eight different concentrations (0.05-10 µM) and the 
parameters evaluated were recovery, matrix effect, linearity, sensitivity, 
precision, accuracy, selectivity, and carry-over [26]. 
 The validated analytical method yielded excellent separation and 
detection of maslinic acid and the I.S. (betulinic acid) in plasma samples, as 
can be seen in Fig. 2.  
 The recovery of maslinic acid was calculated as the ratio between the 
mean peak area of extracted calibration standard samples and the mean 
peak area of the blank plasma samples spiked with this pentacyclic 
triterpene after extraction. Eight different calibration standards in the range 
0.05 ± 10 µM were evaluated and the mean recovery was 99.0 ± 0.9%             
(n = 31). The sensitivity was evaluated on the basis of a signal to noise 
ratio of 3 for the LOD and 10 for the LOQ. The analytical method had an 
adequate sensitivity for the measurement of maslinic acid in plasma samples,             
 
 
 
Figure 2. Representative HPLC-APCI-MS chromatogram obtained in negative mode 
with SIM acquisition at m/z 471.3 for maslinic acid and m/z at 455.5 for betulinic 
acid (I.S.). Rat plasma was obtained 45 min after the oral administration of 50 mg/kg 
of maslinic acid. 
M. Emília Juan & Joana M. Planas 138 
since the LOD was 2 nM and the LOQ was 5 nM. The LOD, verified by 
analyzing six blank plasma samples to which the theoretical concentration 
had been added, yield a concentration of 5.03 ± 0.13 nM with a precision 
of 6.22%. The linearity was assayed within the concentration range of 
0.010-30 µM, which covered the expected concentration range for both the 
i.v. and p.o. administration routes. Linearity was observed in the 
calibration curves over the range 0.010-20 µM with a correlation 
coefficient up to 0.99, losing the linear tendency at 30 µM. The intra-day 
and inter-day precisions of the method were below 5.46% and 8.38%, 
respectively, in all the concentrations evaluated (0.05-20 µM). Finally, 
accuracy was established by comparing the nominal concentrations and the 
calculated concentrations. The deviation was lower than 4.82%. 
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Figure 3. Plasmatic concentrations versus time profile of maslinic acid after single 
i.v. (1 mg/kg) (A) and p.o (50 mg/kg) (B) administration to overnight fasted rats.   
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 The analytical method allowed the detection of maslinic acid after p.o. 
and i.v. administration, and the sampling times were adequate since in both 
cases the elimination phase was properly characterized. Fig. 3 shows the 
plasmatic concentrations versus time of maslinic acid after i.v. and p.o. 
administrations. After p.o. dosing maslinic acid was adequately quantified 
up to 24 h. Nevertheless, in the i.v. administration the blood collected at 8, 
10, and 12 h yielded concentrations of maslinic acid below the LLOQ and 
were below the LOD at 24 h. Therefore, these concentrations were not 
included in the subsequent pharmacokinetic analysis [26].   
 
4.2. Pharmacokinetic analysis of maslinic acid 
 
 The plasmatic concentrations versus time data were analyzed with the 
WinNonlin software to calculate the pharmacokinetic parameters. Non-
compartimental and compartimental analyses were performed. Plasmatic 
data was best adjusted to a two-open compartments with first order 
absorption and linear elimination process (Fig. 4) [26].    
 Following p.o. administration, the peak plasma concentration after oral 
dosing (Cmax) was 4.82 µM and the time to peak plasma concentration 
(Tmax) was 30 min with an oral bioavailability of 6.25% [26]. The low oral 
bioavailability observed was in accordance with the results obtained for 
similar pentacyclic triterpenes [28,29]. A value of 2.3% was reported for         
23-hydroxybetulinic acid after the p.o. administration of 200 mg/kg to mice [29] 
 
 
 
Figure 4. Schematic representation of the pharmacokinetic model that best describes 
the data of plasmatic concentrations of maslinic acid versus time after p.o. and i.v. 
administration.   
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and a 0.7% was indicated for oleanolic acid after the oral dosing of 25 and 
50 mg/kg to mice [28]. The low oral bioavailability found for maslinic acid 
could be attributed to either a poor gastrointestinal absorption or a first-
pass effect of the compound at the intestine or the liver. Maslinic acid have 
been described to exert a chemopreventive activity on colon cancer either 
in vitro in HT-29 colon cancer cells [30] or in vivo in Apc(Min/+) mice 
[31]. Then, if maslinic acid is poorly absorbed in the gut wall, then, the 
large intestine would face important quantities of this pentacyclic 
triterpene, thus becoming a target organ where maslinic acid could elicit 
the described protective activity against colon cancer.  
 The absorbed maslinic acid that reached the blood was distributed to 
the central (0.107 L/kg) and peripheral (1.35 L/kg) compartments. These 
results suggest an extensive distribution into tissues, since the total 
distribution volume (1.46 L/kg) is higher than the total body water in the 
rat (0.17 L/kg, for a mean weight of 0.28 kg). Similar distribution values 
were indicated for oleanolic acid (0.451 L/kg) after the i.v. injection of      
1 mg/kg [28]. The estimated total plasma clearance (CL, 0.348 L/h/kg) was 
slightly lower than that of oleanolic acid (1.98 L/h/kg) [28]. The clearance 
value could be attributed to small hepatic and renal metabolism with 
unaltered renal excretion of this triterpene. Noteworthy, oleanolic, ursolic, 
and maslinic acids have been determined in several organs after a 4-week 
consumption of a diet with 0.5% of these triterpenes, and the liver had the 
largest concentrations followed by the kidney [32]. This results suggest 
that, liver could be an organ for maslinic acid storage, where this 
pentacyclic triterpene could exhibit a protective activity against hepatic 
diseases, as it has been demonstrated in different in vitro experiments 
[16,33]. 
   
5. Metabolism 
 
 The results obtained in the pharmacokinetic study showed a low oral 
bioavailability that could be attributed, in part, to metabolism. Therefore, 
the identification of the biotransformation of maslinic acid constitutes an 
important step in the investigation of this bioactive compound. In addition 
to the role that metabolism may have in affecting the bioavailability by 
influencing the distribution and the rate or the route of excretion, 
metabolites could either contribute to the biological activities or have 
toxicological effects independent of the parent compound [34]. Moreover, 
the identification of metabolites is important since they could act as 
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biomarkers of intake in dietary intervention studies [35]. With the aim of 
gaining insight into the bioavailability of maslinic acid, the metabolism 
was studied in rat plasma obtained after the oral administration of a dose of 
50 mg/kg. Plasma samples were extracted with ethyl acetate prior to 
liquid-chromatography-atmospheric pressure ionization-linear trap 
quadrupole-ORBITRAP-mass spectrometry (LC-LTQ-ORBITRAP-MS) 
analysis [36]. This high-resolution mass spectrometer provides robust, 
accurate mass data that enables the unambiguous identification of 
metabolites. Plasma was screened for metabolites with the assumption that 
this bioactive compound from the diet could be considered as a xenobiotic 
by the organism and consequently, the detoxification processes that 
increased the hydrophilicity of maslinic acid could be activated [37]. 
Hence, metabolites arising from phase I reactions, which are based on 
oxidation, reduction, and hydrolysis processes, and phase II 
biotransformations, such as glucoronidation, sulfation, methylation, 
acetylation, and glutathione conjugation were searched in the samples. The 
results obtained showed that only compounds arising from phase I 
reactions were found. The molecule of maslinic acid was modified in order 
to yield four monohydroxylated derivatives (M1a-M1d), one 
monohydroxylated and dehydrogenated metabolite (M2) as well as two 
dihydroxylated and dehydrogenated compounds (M3a-M3b) [37]. 
 Metabolism of maslinic acid has only been investigated in vitro with 
the use of fungi such as Cunninghamella [38] and Rhizomucor [39,40]. 
These microorganisms are commonly used in the evaluation of the 
metabolism of drugs and xenobiotics since they express cytochrome P450 
(CYP) enzymes that allow equivalent phase I reactions to mammalian 
metabolism. In these studies, the chemical structure of the derivatives was 
elucidated based on the use of nuclear magnetic resonance and high-
resolution mass spectra analyses. Therefore, the hydroxyl of the mono-
hydroxytaled metabolite (M1-a, M1-b, M1-c, M1-d) could be compatible 
with the metabolites previously described [38,39,40]. The transformations 
found after incubations with Cunninghamella blakesleana were three 
different monohydroxylated derivatives (7β-hydroxy, 15α-hydroxy,                
13β-hydroxy with double bound migration) [38]. When Rhizomucor miehei 
was used, monohydroxylation was also observed, but in this case the 
addition of the hydroxyl group took place at the angular methyl group on 
position 30 [39]. 
 Moreover, the monohydroxylated and dehydrogenated metabolite (M2) 
could be formed by a hydroxylation at C-11, followed by a 
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dehydrogenation to ketone or by the formation of an epoxy group between 
C-11 and C-12, as previously suggested [39,40]. The dihydroxylated and 
dehydrogenated metabolite (M3-a, M3-b) could be compatible with the 
hydroxylation at C-30 and the epoxy between C-11 and C-12 [39]. 
However, the two observed metabolites could also be due to other 
structures not detected in the incubations of maslinic acid with fungi [38-
40] such as the combinations of these functionalizations or the presence of 
a hydroxyl group in one position and a ketone in another carbon.  
 The only in vivo studies were performed with pentacyclic triterpenes 
similar to maslinic acid and confirmed that the biotransformation of these 
compounds occurs mainly by phase I reactions [41,42]. The oral 
administration of 12.5 mg/kg of boswellic acids to female albino Wistar 
rats gave in plasma two monohydroxylated derivatives [56]. Incubation of 
oleanolic acid [28] and boswellic acids [41,42] with rat and human liver 
microsomes also indicated that hydroxylation is the main metabolic route 
for pentacyclic triterpenes.  
 The quantification by LC-APCI-MS showed that maslinic acid was the 
most abundant compound in plasma (81.8%), which indicates that 
metabolism is low. It was followed by metabolite M2 with a 13.2% and 
M1-a with a 2.5%. The other metabolites (M1-b, M1-c, M1-d, M3-a,    
M3-b) were found in minor amounts since all of them accounted for only a 
2.5% [37]. Overall, the study gives a comprehensive insight into the 
metabolite profile of maslinic acid, thus increasing our knowledge about 
the bioavailability of this bioactive food component. 
 
6. Conclusion 
 
 Maslinic acid is a bioactive compound that targets a wide variety of 
molecules or metabolic pathways suggesting its putative use as 
nutraceutical. However, research on maslinic acid is currently in the early 
stages of the pre-clinical phase. Consequently, the present chapter 
summarizes the current knowledge about the safety and the bioavailability 
of maslinic acid after oral administration. A liquid-liquid extraction 
method followed by LC-APCI-MS was validated to determine of maslinic 
acid in blood. Analysis of plasmatic concentrations indicated that this 
bioactive compound was absorbed with a peak plasmatic concentration at 
30 min and oral bioavailability of 6.25%. Metabolism was subsequently 
screened and revealed that maslinic acid is the main compound in plasma 
although it undergoes mainly phase I metabolism through hydroxylation 
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and oxidation reactions, leading to seven metabolites. In summary, the 
present results show that maslinic acid can be safely administered by the 
oral route and provides a comprehensive knowledge on the bioavailability 
and metabolism as a first step on the use of this bioactive compound as a 
nutraceutical.  
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